Please login to the form below

Not currently logged in
Email:
Password:

Ono Pharmaceuticals

This page shows the latest Ono Pharmaceuticals news and features for those working in and with pharma, biotech and healthcare.

Ono faces steep price cut for Opdivo in Japan

Ono faces steep price cut for Opdivo in Japan

Japan has followed through on plans for an out-of-cycle price cut for Ono Pharmaceuticals' cancer drug Opdivo, lowering it by 50%. ... Ono has said it is considering filing an objection to the decision, on the grounds that the move will disrupt its

Latest news

  • Immunotherapy and future directions in oncology Immunotherapy and future directions in oncology

    To date, three immune checkpoint inhibitors reached the market: ipilimumab (Yervoy, Bristol-Myers Squibb), nivolumab (Opdivo, Bristol-Myers Squibb and Ono Pharmaceuticals), and pembrolizumab (Keytruda, Merck &Co.) - all three marketed for

  • Ipragliflozin beats diabetes rivals to Japanese approval Ipragliflozin beats diabetes rivals to Japanese approval

    The Japanese regulatory authorities have cleared ipragliflozin under the Suglat trade name for the treatment of type 2 diabetes, beating rivals Ono Pharmaceuticals/AstraZeneca and Johnson &Johnson who have filed their

  • Promising new agents for multiple myeloma Promising new agents for multiple myeloma

    Chemotherapy: Proteasome inhibitors. There are currently two approved proteasome inhibitors - bortezomib (Velcade, Millennium Pharmaceuticals) and carfilzomib (Kyprolis, Ono Pharmaceutical) - both of which are administered intravenously. ... A third

  • Salix licenses Progenics' Relistor

    Salix Pharmaceuticals has licensed worldwide rights excluding Japan to the opioid-induced constipation drug Relistor from Progenics Pharmaceuticals. ... Salix will fund all development, registration and commercialisation activities for Relistor, except

  • R&D news in brief

    The drug, which was licensed from Japan's Ono Pharmaceuticals, is in a race to market with its rival CCR inhibitor, Pfizer's Maraviroc.

More from news
Approximately 1 fully matching, plus 7 partially matching documents found.

Latest Intelligence

  • Deal Watch July 2016 Deal Watch July 2016

    In the second immuno-therapy deal to make the top 20 this month ONO Pharmaceuticals paid $12.5m upfront for the rights to develop Celyad's phase I product, allogeneic ... Acquisition. 325. Celyad/ ONO Pharmaceutical. Allogeneic NKR-2 T-cell immunotherapy.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
3 Monkeys Zeno

3 Monkeys Zeno is an award winning global creative communications consultancy – home to a collective of creative and strategic...

Latest intelligence

#DemandDiversity: For International Women's Day, we ask... why do women often suffer from more side effects than men?
Women are largely prescribed exactly the same treatment regimens as men, with no account for the underlying differences in physiology and drug metabolism between the sexes....
Good design saves lives
Good design and creative thinking are essential if we are to improve on existing problems in new ways, which is why design and creativity within healthcare is vital. Health is...
Why you must understand the pricing of patient recruitment companies
Recruiting a diverse range of patients and engaging with them for your clinical trial isn’t an easy task, which means you might turn to patient recruitment companies, like us, who...

Infographics